Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 34
Filtrar
1.
J Appl Microbiol ; 134(12)2023 Dec 01.
Artigo em Inglês | MEDLINE | ID: mdl-37977856

RESUMO

AIMS: To demonstrate the in vitro activity of orally available antibiotics against Staphylococcus aureus isolated from bone or orthopedic implant materials. The biofilm eradication of the combination of three antibiotics was also assessed. METHODS AND RESULTS: Clinical isolates from orthopedic infection samples were collected, and S. aureus isolates were classified according to their biofilm production and composition. Almost all S. aureus isolates (n = 36, 97.3%) produced biofilm and the major biofilm components were polysaccharides. Antimicrobial susceptibility was determined in planktonic (minimal inhibitory concentration; MIC) and biofilm cells (minimal biofilm eradication concentration; MBEC) using the MBEC Calgary Device. Overall, the MBEC ranged higher than the MIC. When combined at borderline-susceptible concentrations, moxifloxacin-rifampin and doxycycline-rifampin were both able to eradicate biofilms in a third of the strains whereas the doxycycline-moxifloxacin combination proved ineffective at eradicating biofilm, inhibiting it only in three strains. CONCLUSIONS: We propose rifampin in combination with moxifloxacin or doxycycline for the design of clinical trials of bone and/or orthopedic device infection without proper debridement or material retention.


Assuntos
Antibacterianos , Infecções Estafilocócicas , Humanos , Antibacterianos/farmacologia , Antibacterianos/uso terapêutico , Staphylococcus aureus , Rifampina/farmacologia , Moxifloxacina/farmacologia , Moxifloxacina/uso terapêutico , Doxiciclina/farmacologia , Plâncton , Infecções Estafilocócicas/tratamento farmacológico , Biofilmes , Testes de Sensibilidade Microbiana
2.
Arch. argent. pediatr ; 121(5): e202201449, oct. 2023. ilus
Artigo em Inglês, Espanhol | LILACS, BINACIS | ID: biblio-1509734

RESUMO

La osteomielitis primaria de esternón es muy infrecuente en niños, con menos de 100 casos publicados hasta la actualidad. Su presentación clínica es a menudo inespecífica, lo que causa un retraso en el diagnóstico. Se presentan dos nuevos casos de osteomielitis primaria de esternón. Ambos referían un cuadro de fiebre, malestar general, dolor torácico y rechazo del decúbito, con eritema preesternal en uno de los casos. La velocidad de sedimentación globular y la proteína C-reactiva estaban elevadas en ambos casos. El diagnóstico se confirmó mediante estudios de imagen y en un caso se aisló Staphylococcus aureus sensible a meticilina en el hemocultivo. Ambos se recuperaron sin complicaciones con tratamiento antibiótico. Debe tenerse en cuenta la osteomielitis primaria de esternón en el diagnóstico diferencial del dolor torácico, especialmente si se acompaña de fiebre, signos inflamatorios locales, intolerancia al decúbito o elevación de reactantes de fase aguda.


Primary sternal osteomyelitis is very rare in children, with less than 100 cases published to date. Its clinical presentation is often non-specific, which results in a diagnostic delay. Here we describe 2 new cases of primary sternal osteomyelitis. Both referred fever, malaise, chest pain, and refusal to lie down, with pre-sternal erythema in one of the cases. The erythrocyte sedimentation rate and C-reactive protein values were high in both cases. The diagnosis was confirmed by imaging studies; methicillin-sensitive Staphylococcus aureus was isolated in the blood culture of one of them. Both recovered without complications with antibiotic treatment. Primary sternal osteomyelitis should be considered in the differential diagnosis of chest pain, especially if accompanied by fever, local inflammatory signs, intolerance to lying down, or increased acute phase reactants.


Assuntos
Humanos , Feminino , Lactente , Criança , Osteomielite/diagnóstico , Osteomielite/tratamento farmacológico , Infecções Estafilocócicas/diagnóstico , Infecções Estafilocócicas/tratamento farmacológico , Staphylococcus aureus , Dor no Peito/tratamento farmacológico , Diagnóstico Tardio , Febre , Antibacterianos/uso terapêutico
3.
Arch Argent Pediatr ; 121(5): e202201449, 2023 10 01.
Artigo em Inglês, Espanhol | MEDLINE | ID: mdl-36724129

RESUMO

Primary sternal osteomyelitis is very rare in children, with less than 100 cases published to date. Its clinical presentation is often non-specific, which results in a diagnostic delay. Here we describe 2 new cases of primary sternal osteomyelitis. Both referred fever, malaise, chest pain, and refusal to lie down, with pre-sternal erythema in one of the cases. The erythrocyte sedimentation rate and C-reactive protein values were high in both cases. The diagnosis was confirmed by imaging studies; methicillin-sensitive Staphylococcus aureus was isolated in the blood culture of one of them. Both recovered without complications with antibiotic treatment. Primary sternal osteomyelitis should be considered in the differential diagnosis of chest pain, especially if accompanied by fever, local inflammatory signs, intolerance to lying down, or increased acute phase reactants.


La osteomielitis primaria de esternón es muy infrecuente en niños, con menos de 100 casos publicados hasta la actualidad. Su presentación clínica es a menudo inespecífica, lo que causa un retraso en el diagnóstico. Se presentan dos nuevos casos de osteomielitis primaria de esternón. Ambos referían un cuadro de fiebre, malestar general, dolor torácico y rechazo del decúbito, con eritema preesternal en uno de los casos. La velocidad de sedimentación globular y la proteína C-reactiva estaban elevadas en ambos casos. El diagnóstico se confirmó mediante estudios de imagen y en un caso se aisló Staphylococcus aureus sensible a meticilina en el hemocultivo. Ambos se recuperaron sin complicaciones con tratamiento antibiótico. Debe tenerse en cuenta la osteomielitis primaria de esternón en el diagnóstico diferencial del dolor torácico, especialmente si se acompaña de fiebre, signos inflamatorios locales, intolerancia al decúbito o elevación de reactantes de fase aguda.


Assuntos
Osteomielite , Infecções Estafilocócicas , Criança , Humanos , Diagnóstico Tardio , Staphylococcus aureus , Antibacterianos/uso terapêutico , Infecções Estafilocócicas/diagnóstico , Infecções Estafilocócicas/tratamento farmacológico , Osteomielite/diagnóstico , Osteomielite/tratamento farmacológico , Febre , Dor no Peito/tratamento farmacológico
4.
Viral Immunol ; 36(4): 241-249, 2023 05.
Artigo em Inglês | MEDLINE | ID: mdl-36800236

RESUMO

Individuals with no known comorbidities or risk factors may develop severe coronavirus disease 2019 (COVID-19). The present study assessed the effect of certain host polymorphisms and viral lineage on the severity of COVID-19 among hospitalized patients with no known comorbidities in Mexico. The analysis included 117 unrelated hospitalized patients with COVID-19. Patients were stratified by whether they required intensive care unit (ICU) admission: the ICU group (n = 40) and non-ICU group (n = 77). COVID-19 was diagnosed on the basis of a positive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) reverse transcription-polymerase chain reaction (RT-PCR) assay and clinical and radiographic criteria. The presence of the IL1B-31 (T/C) polymorphism was determined for all patients using PCR and nucleotide sequencing. Genotyping of the IL-4 (-590, T/C) and IL-8 (-251, T/A) polymorphisms was performed by the amplification refractory mutation system-PCR method. Genotyping of IL1-RN was performed using PCR. Viral genome sequencing was performed using the ARTIC Network amplicon sequencing protocol using a MinION. Logistic regression analysis identified the carriage of IL-1 B*-31 *C as an independent potential risk factor (odds ratio [OR] = 3.1736, 95% confidence interval [CI] = 1.0748-9.3705, p = 0.0366) for ICU admission and the presence of IL-RN*2 as a protective factor (OR = 0.4371, 95% CI = 0.1935-0.9871, p = 0.0465) against ICU admission. Under the codominant model, the CC genotype of IL1B-31 significantly increased the risk of ICU admission (OR: 6.38, 95% CI: 11.57-25.86, p < 0.024). The IL1B-31 *C-IL-4-590 *T haplotype increased the risk of ICU admission (OR = 2.53, 95% CI = 1.02-6.25, p = 0.047). The 42 SARS-CoV-2 genomes sequenced belonged to four clades, 20A-20D. No association was detected between SARS-CoV-2 clades and ICU admission or death. Thus, in patients with no known comorbidities or risk factors, the IL1B-31*C proinflammatory allele was observed to be associated with the risk of ICU admission owing to COVID-19.


Assuntos
COVID-19 , Humanos , COVID-19/genética , SARS-CoV-2/genética , Alelos , Interleucina-4 , Hospitalização
5.
Vaccines (Basel) ; 10(5)2022 Apr 21.
Artigo em Inglês | MEDLINE | ID: mdl-35632412

RESUMO

Information regarding the efficacy of the recombinant adenovirus type-5-vectored (CanSino Bio) vaccine against the COVID-19 disease in a real-life setting is limited. A retrospective cohort study was carried out in the teaching university community of the metropolitan area of Monterrey, Mexico, through a four-section survey, and during the COVID-19 delta wave. Determination of IgG antibodies against SARS-CoV-2 spike (S) protein was performed in a subset of participants vaccinated with CanSino Bio. A total of 7468 teachers responded to the survey, and 6695 of them were fully vaccinated. Of those, 72.7% had CanSino Bio, 10.3% Pfizer, 8.4% AstraZeneca, 1.2% Moderna, and 2.7% others. Symptomatic breakthrough infections were recorded in those vaccinated with CanSino Bio (4.1%), AstraZeneca (2.1%), and Pfizer (2.2%). No difference was found between CanSino Bio and other vaccines regarding hospitalization, the need for mechanical ventilation, and death. For CanSino Bio recipients, anti-S antibodies were >50 AU/mL in 73.2%. In conclusion, primary breakthrough symptomatic infections were higher in the CanSino vaccinated group compared to other brands. Individuals with a previous infection had higher antibody levels than those who were reinfected and without infection. A boosted dose of CanSino is recommended for those individuals without a previous infection.

6.
J Hazard Mater ; 433: 128764, 2022 07 05.
Artigo em Inglês | MEDLINE | ID: mdl-35390620

RESUMO

Lindane and other 1,2,3,4,5,6-hexachlorocyclohexane (HCH) isomers are persistent organic pollutants highly hydrophobic, which hampers their availability and biodegradation. This work aimed at (i) investigating genes encoding enzymes involved in HCH degradation in the bacterium Sphingobium sp. D4, (ii) selecting strains, from a collection of environmental isolates, able to mobilize HCHs from contaminated soil, and (iii) analysing the biodegradation of HCHs by strain D4 in co-culture with HCH-mobilizing strains or when cultivated with root exudates. Fragments of the same size and similar sequence to linA and linB genes were successfully amplified. Two isolates, Streptomyces sp. M7 and Rhodococcus erythropolis ET54b able to produce emulsifiers and to mobilize HCH isomers from soil were selected. Biodegradation of HCH isomers by strain D4 was enhanced when co-inoculated with HCH mobilizing strains or when cultivated with root exudates. The degrader strain D4 was able to decompose very efficiently HCHs isomers, reducing their concentration in soil slurries by more than 95% (from an average initial amount of 50 ± 8 mg HCH kg-1 soil) in 9 days. The combination of HCH-degrading and HCH-mobilizing strains can be considered a promising inoculum for future soil bioremediation studies using bioaugmentation techniques or in combination with plants in rhizodegradation assays.


Assuntos
Poluentes do Solo , Sphingomonadaceae , Biodegradação Ambiental , Técnicas de Cocultura , Exsudatos e Transudatos/química , Exsudatos e Transudatos/metabolismo , Hexaclorocicloexano/química , Solo/química , Poluentes do Solo/metabolismo , Sphingomonadaceae/genética , Sphingomonadaceae/metabolismo
7.
Medisan ; 26(2)abr. 2022. tab
Artigo em Espanhol | LILACS, CUMED | ID: biblio-1405801

RESUMO

Introducción: Los trastornos temporomandibulares constituyen una condición dolorosa que afecta los músculos de la masticación, la articulación temporomandibular, así como varias estructuras anatómicas del sistema estomatognático. Objetivo: Evaluar la efectividad de la electroacupuntura en pacientes con síndrome de dolor miofacial asociado a disfunción de la articulación temporomandibular. Métodos: Se realizó un estudio cuasiexperimental de intervención terapéutica en 80 pacientes asistidos en el Hospital General Docente Dr. Juan Bruno Zayas Alfonso de Santiago de Cuba, desde noviembre del 2018 hasta igual mes de 2021, quienes padecían dolor miofacial por disfunción en las articulaciones temporomandibulares. Estos fueron asignados de forma alterna en dos grupos terapéuticos de 40 integrantes cada uno: el de estudio, al que se le aplicó electroacupuntura, y el de control, el cual recibió medicación farmacológica convencional; luego, se les fue evaluando clínicamente al tercero, quinto, séptimo y décimo días de iniciadas las terapias. Las variables fueron procesadas estadísticamente aplicando el porcentaje como medida de resumen y la prueba de la Χ2 para estimar diferencias en cuanto al tiempo promedio de buena evolución, con un nivel de significación de 0,05. Resultados: Antes de comenzar los tratamientos, el dolor era intenso en la mayoría de los pacientes de ambos grupos; sin embargo, al tercer día de iniciada la intervención terapéutica, la evolución había sido buena en 45,0 % del grupo de estudio y 32,5 % del grupo de control; al quinto día este porcentaje había aumentado a 60,0 en los que recibieron electroacupuntura, pero se mantuvo igual en los que fueron tratados convencionalmente. Al finalizar la intervención se había logrado la recesión o el alivio del dolor miofacial en 97,5 % de los casos y en 90,0 % de los controles. Conclusiones: La electroacupuntura resultó clínicamente más efectiva para paliar el dolor miofacial producido por los trastornos temporomandibulares, con un menor tiempo promedio de buena respuesta terapéutica.


Introduction: The temporomandibular disorders constitute a painful condition that affects the mastication muscles, the temporomandibular joint, as well as several anatomical structures of the stomatognathic system. Objective: To evaluate the effectiveness of electroacupuncture in patients with syndrome of miofacial pain associated with temporomandibular joint dysfunction. Methods: A quasi-experiment study of therapeutic intervention in 80 patients assisted in Dr. Juan Bruno Zayas Alfonso Teaching General Hospital from Santiago de Cuba, was carried out from November, 2018 to the same month in 2021, who suffered from miofacial pain due to dysfunction in the temporomandibular joint. These were assigned in an alternating way in two therapeutic groups of 40 members each one: that of study, to which electroacupuncture was applied, and that of control, which received conventional pharmacological medication; then, they were clinically evaluated at the third, fifth, seventh and tenth days after the therapy. The variables were statistically processed applying the percentage as summary measure and the chi-square test to estimate differences as for the average time of good evolution, with a level of significance of 0.05. Results: Before beginning the therapy, the pain was intense in most of the patients of both groups; however, at the third day of the therapies, the evolution had been good in 45.0 % of the study group and 32.5 % of the control group, and the fifth day this percentage had increased at 60.0 in those that received electroacupuncture, but stayed equally in those that were treated conventionally. When concluding the intervention recession or relief of the miofacial pain in 97.5 % of the cases and in 90.0 % of the controls was achieved. Conclusions: The electroacupuncture was clinically more effective than the conventional medication to palliate the miofacial pain caused by the temporomandibular disorders, with a less average time of good therapeutic response.


Assuntos
Articulação Temporomandibular , Transtornos da Articulação Temporomandibular , Eletroacupuntura , Dor Facial
8.
Viruses ; 14(1)2022 01 14.
Artigo em Inglês | MEDLINE | ID: mdl-35062359

RESUMO

SARS-CoV-2 variants of concern (VOCs) or of interest (VOIs) causing vaccine breakthrough infections pose an increased risk to worldwide public health. An observational case-control study was performed of SARS-CoV-2 vaccine breakthrough infections in hospitalized or ambulatory patients in Monterrey, Mexico, from April through August 2021. Vaccination breakthrough was defined as a SARS-CoV-2 infection that occurred any time after 7 days of inoculation with partial (e.g., first dose of two-dose vaccines) or complete immunization (e.g., second dose of two-dose vaccines or single-dose vaccine, accordingly). Case group patients (n = 53) had partial or complete vaccination schemes with CanSino (45%), Sinovac (19%), Pfizer/BioNTech (15%), and AstraZeneca/Oxford (15%). CanSino was administered most frequently in ambulatory patients (p < 0.01). The control group (n = 19) received no COVID-19 vaccines. Among SARS-CoV-2 variants detected by whole-genome sequencing, VOC Delta B.1.617.2 predominated in vaccinated ambulatory patients (p < 0.01) and AY.4 in hospitalized patients (p = 0.04); VOI Mu B.1.621 was detected in four (7.55%) vaccinated patients. SARS-CoV-2 breakthrough infections in our hospital occurred mostly in patients vaccinated with CanSino due to the higher prevalence of CanSino vaccine administration in our population. These patients developed mild COVID-19 symptoms not requiring hospitalization. The significance of this study lies on the detection of SARS-CoV-2 variants compromising the efficacy of local immunization therapies in Monterrey, Mexico.


Assuntos
COVID-19/virologia , SARS-CoV-2/isolamento & purificação , Adulto , Idoso , COVID-19/epidemiologia , Vacinas contra COVID-19 , Estudos de Casos e Controles , Feminino , Hospitalização , Hospitais Universitários , Humanos , Masculino , México/epidemiologia , Pessoa de Meia-Idade , Filogenia , Prevalência , SARS-CoV-2/classificação , SARS-CoV-2/genética , Vacinação , Eficácia de Vacinas , Sequenciamento Completo do Genoma
9.
Ginecol. obstet. Méx ; Ginecol. obstet. Méx;90(9): 803-808, ene. 2022. graf
Artigo em Espanhol | LILACS-Express | LILACS | ID: biblio-1430442

RESUMO

Resumen INTRODUCCIÓN: La tuberculosis sigue siendo un problema de salud pública global: alrededor de un cuarto de la población mundial está infectada con el bacilo de la tuberculosis, pero solo 5 a 15% realmente resultarán con la enfermedad. Pese a los esfuerzos por controlar la infección, hoy en día es la principal causa de muerte producida por un único agente infeccioso. La forma extrapulmonar es rara, y la genital suele manifestarse con esterilidad, en otros simula un cáncer de ovario avanzado, incluidas la masa anexial y la ascitis, pérdida de peso y elevación del marcador tumoral Ca125. El diagnóstico diferencial prequirúrgico es complejo, de ahí que a la mayoría de las pacientes se les indique una intervención quirúrgica innecesaria. CASO CLÍNICO: Paciente de 29 años con diagnóstico de formación anexial sospechosa de malignidad que se trató de manera conservadora hasta conseguir su regresión total. Además, se efectuó una revisión de la bibliografía relacionada con esta infrecuente entidad. CONCLUSIÓN: La conjunción de ascitis, masa pélvica y elevación del marcador Ca125 puede corresponder al diagnóstico de cáncer de ovario avanzado, ello sin olvidar la posibilidad de tuberculosis extraperitoneal en pacientes con antecedente de tuberculosis o procedentes de zonas endémicas. El diagnóstico es complejo, sobre todo por la baja incidencia en nuestro medio, que a menudo requiere laparoscopias exploradoras para confirmar el origen de las lesiones.


Abstract INTRODUCTION: Tuberculosis remains a global public health problem: about a quarter of the world's population is infected with the tuberculosis bacillus, but only 5-15% will actually develop the disease. Despite efforts to control the infection, today it is the leading cause of death from a single infectious agent. The extrapulmonary form is rare, and the genital form usually manifests with sterility, in others it simulates advanced ovarian cancer, including adnexal mass and ascites, weight loss and elevation of the tumor marker Ca125. The pre-surgical differential diagnosis is complex, hence most patients are indicated for unnecessary surgery. CLINICAL CASE: A 29-year-old patient with a diagnosis of adnexal formation suspicious for malignancy was treated conservatively until complete regression was achieved. In addition, a review of the existing literature related to this rare entity was performed. CONCLUSION: The conjunction of ascites, pelvic mass and elevated Ca125 marker may correspond to the diagnosis of advanced ovarian cancer, without forgetting the possibility of extraperitoneal tuberculosis in patients with a history of tuberculosis or from endemic areas. Diagnosis is complex, especially due to the low incidence in our environment, which often requires exploratory laparoscopy to confirm the origin of the lesions.

10.
Ginecol. obstet. Méx ; Ginecol. obstet. Méx;90(4): 307-315, ene. 2022. tab
Artigo em Espanhol | LILACS-Express | LILACS | ID: biblio-1385027

RESUMO

Resumen OBJETIVO: Exponer los desenlaces quirúrgicos de las pacientes intervenidas por cáncer de endometrio, analizar si existen puntos de mejora en nuestra práctica clínica y aportar más datos a la evidencia publicada, para ayudar al avance en el tratamiento quirúrgico de las pacientes con esta enfermedad MATERIALES Y MÉTODOS: Estudio observacional, descriptivo y retrospectivo llevado a cabo en la Unidad de Oncología Ginecológica del Hospital Regional Virgen Macarena de Sevilla, España, entre junio de 2013 y febrero de 2020. Se reunieron los reportes quirúrgicos de pacientes intervenidas por alguna afección endometrial premaligna o maligna. Variables de estudio: edad, IMC, cirugías previas, diagnóstico histopatológico y estadio, vía de acceso quirúrgico y terapia coadyuvante. Se exponen los desenlaces relacionados con complicaciones quirúrgicas y tasa de curación, así como el tiempo de intervención, vía de acceso quirúrgico y estancia hospitalaria. RESULTADOS: Se estudiaron 250 pacientes, la mayoría (76%) con diagnóstico de adenocarcinoma endometrioide de endometrio. La vía de acceso quirúrgico más utilizada fue la laparoscopia (51.6%), con un porcentaje de complicaciones intraoperatorias del 10% y posoperatorias del 9.2%. El 88.4% de las pacientes permanece viva y libre de enfermedad después del tratamiento, con recaídas solo en el 11.6% y 8% de fallecimientos. CONCLUSIONES: El tratamiento inicial de elección, en pacientes con hiperplasia con atipias o cáncer de endometrio en estadios tempranos, es la cirugía, mediante histerectomía, doble anexectomía y en algunos casos linfadenectomía asociada. La elección de la vía quirúrgica de acceso debe individualizarse a las condiciones particulares de cada paciente. La laparoscopia ofrece múltiples ventajas, es una técnica en auge y cada día más practicada.


Abstract OBJECTIVE: To expose the surgical outcomes of patients operated on for endometrial cancer, to analyze if there are points of improvement in our clinical practice and to contribute more data to the published evidence, to help advance the surgical treatment of patients with this disease. MATERIALS AND METHODS: Observational, descriptive, and retrospective study carried out in the Gynecologic Oncology Unit of the Virgen Macarena Regional Hospital of Seville, Spain, between June 2013 and February 2020. Surgical reports of patients operated on for any premalignant or malignant endometrial condition were collected. Study variables: age, BMI, previous surgeries, histopathological diagnosis and stage, surgical access route and adjuvant therapy. Outcomes related to surgical complications and cure rate are presented, as well as operation time, surgical access route and hospital stay. RESULTS: 250 patients were studied, the majority (76%) with a diagnosis of endometrioid endometrial adenocarcinoma. The most used surgical access route was laparoscopy (51.6%), with a percentage of intraoperative complications of 10% and postoperative complications of 9.2%. 88.4% of patients remain alive free of disease after treatment, with relapses in only 11.6% and 8% deaths. CONCLUSIONS: The initial treatment of choice in patients with hyperplasia with atypia or early-stage endometrial cancer is surgery, by hysterectomy, double adnexectomy and in some cases associated lymphadenectomy. The choice of surgical approach must be individualized to the conditions of each patient. Laparoscopy offers multiple advantages; it is a technique that is on the rise and is being used more and more frequently.

11.
J Microbiol Immunol Infect ; 54(5): 787-793, 2021 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-34294593

RESUMO

OBJECTIVE: We aimed to analyze clinical outcomes from patients with severe COVID-19 pneumonia that received either baricitinib plus dexamethasone or dexamethasone monotherapy. METHODOLOGY: We performed a retrospective comparative study. Data from hospitalized patients with severe COVID-19 pneumonia (saturation <93%, bilateral pulmonary infiltrates) that were treated with baricitinib plus dexamethasone or dexamethasone were collected. Our primary objective was to compare overall mortality and secondly to compare progression to mechanical ventilation and over infection rates. RESULTS: A total of 793 patients were assessed for inclusion criteria, 596 were excluded and 197 were analyzed for primary outcome: 123 in the baricitinib plus dexamethasone group and 74 in the dexamethasone monotherapy group. The mean age was 59.9 years (SD ± 14.5) and 62.1% (123/197) were male. 42.9% (85/197) of the cases required ICU admission and 25.8% (51/197) underwent invasive mechanical ventilation (IMV). Overall thirty-day mortality was 27.9% (55/197); Mortality was significantly lower in the baricitinib plus dexamethasone group compared to the dexamethasone monotherapy group (20.3% vs 40.5%, P = <.05). There was no difference in hospital acquired infections between both groups. CONCLUSION: Thirty-day mortality was significantly lower in patients with COVID-19 pneumonia treated with baricitinib plus dexamethasone versus dexamethasone monotherapy. No difference was observed in progression to invasive mechanical ventilation and hospital acquired infections.


Assuntos
Azetidinas/uso terapêutico , Tratamento Farmacológico da COVID-19 , Dexametasona/uso terapêutico , Purinas/uso terapêutico , Pirazóis/uso terapêutico , Sulfonamidas/uso terapêutico , Idoso , Quimioterapia Combinada , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Estudos Retrospectivos , SARS-CoV-2/efeitos dos fármacos
13.
Ginecol. obstet. Méx ; Ginecol. obstet. Méx;89(10): 832-838, ene. 2021.
Artigo em Espanhol | LILACS-Express | LILACS | ID: biblio-1394371

RESUMO

Resumen ANTECEDENTES: La leucemia mieloide aguda es el cuarto cáncer diagnosticado con más frecuencia durante el embarazo. En la actualidad, su tratamiento en las distintas etapas del embarazo sigue suponiendo un desafío diagnóstico y terapéutico para los obstetras, oncólogos y hematólogos. OBJETIVO: Reportar el caso clínico de una paciente embarazada a quien se diagnosticó leucemia mieloide aguda en el primer trimestre, el seguimiento efectuado y el tratamiento propuesto. Además, se revisa la bibliografía existente en relación con este cáncer. CASO CLÍNICO: Paciente de 33 años, embarazada, con 12 + 5 semanas de amenorrea. Se envió al servicio de Hematología debido al hallazgo de pancitopenia en los estudios de laboratorio del primer trimestre. Enseguida de completar el estudio y tomar una biopsia de médula ósea, se estableció el diagnóstico de leucemia mieloblástica aguda NMP1 y FLT-3 negativos, con 20% de blastos. El embarazo finalizó sin contratiempos a las 15 semanas, mediante interrupción voluntaria, luego de recibir información del diagnóstico, pronóstico y riesgo de teratogenia del tratamiento. En la actualidad, la paciente permanece en lista de espera para trasplante de médula ósea histocompatible. CONCLUSIONES: La correcta atención al control de los análisis de laboratorio, propios del embarazo, puede permitir un diagnóstico temprano que permita iniciar un tratamiento inmediato, decisivo para el pronóstico. Todo esto, además de la atención y asesoramiento multidisciplinario, resulta esencial para asegurar el bienestar de la madre y del feto.


Abstract BACKGROUND: Acute myeloid leukemia is the fourth most frequently cancer in association with pregnancy. Nowadays, clinical management of AML occurring during pregnancy is a diagnostic and therapeutic challenging. OBJECTIVE: To report the unpublished case of pregnant diagnosed with acute myeloid leukemia in the first trimester of pregnancy, as well as the follow-up carried out and the proposed treatment. We also review the existing literature in relation to this entity. CLINICAL CASE: 33-year-old patient, at 12+5 weeks of pregnancy. She was admitted to the hematology service due to the discovery of pancytopenia in the laboratory tests performed in the first trimester. After completing the study and performing a bone marrow biopsy, the patient was diagnosed with NMP1 and FLT-3 Negative acute myeloblastic leukemia, with 20% blasts. The pregnancy ended without incident at 15 weeks, by means of a voluntary interruption of the pregnancy, after receiving information on the diagnosis, prognosis and risk of teratogenicity from the treatment. Currently, the patient is on the waiting list for histocompatibility bone marrow transplant. CONCLUSIONS: The importance of analytical control during pregnancy can allow an early diagnosis, to establish an immediate treatment, key for the prognosis. All this, in addition to the multidisciplinary approach and advice, is essential to ensure maternal and fetal well-being.

14.
Rev. chil. obstet. ginecol. (En línea) ; Rev. chil. obstet. ginecol;85(6): 670-677, dic. 2020. ilus
Artigo em Espanhol | LILACS | ID: biblio-1508023

RESUMO

INTRODUCCIÓN: Los leiomiomas uterinos son el tumor pélvico más frecuente en la mujer, derivan de las células musculares lisas del miometrio y pueden localizarse en cualquiera de las porciones uterinas. Se clasifican según su relación con las diferentes capas del útero mediante la clasificación de la FIGO. Pueden ser asintomáticos o producir síntomas como sangrado, problemas reproductivos o dolor por compresión de estructuras vecinas. El tratamiento puede ser médico o quirúrgico, teniendo dentro de este último grupo, la posibilidad de realizar una miomectomía o una histerectomía total o subtotal. La histerectomía subtotal permite mantener el cérvix uterino, de tal forma que la técnica quirúrgica es más sencilla, sin embargo, requiere de la morcelación de la pieza para su extracción; mientras que la histerectomía total elimina el riesgo de recidiva de la patología uterocervical, aunque precisa de una mayor curva de aprendizaje. CASO CLÍNICO: Presentamos el caso de una paciente de 52 años a la que se le realizó una histerectomía supracervical laparoscópica por miomas. Posteriormente, se objetivó la aparición de un nuevo mioma en el remanente cervical, que requirió de una traquelectomía vía vaginal. CONCLUSIÓN: La histerectomía subtotal laparoscópica en úteros con múltiples miomas puede tener como efecto adverso la recidiva miomatosa en el cérvix o la aparición de miomas parasitarios secundarios a la morcelación uterina no estanca. Además, implica continuar con el cribado para la prevención del cáncer de cérvix uterino.


BACKGROUND: Uterine leiomyomas are the most frequent pelvic tumor in women. They derive from smooth muscle cells of the myometrium and can be in any of the uterine parts. They are classified according to their relationship with the different layers of the uterus by the FIGO classification. Uterine leiomyomas can be asymptomatic or produce symptoms such as compression pain, reproductive problems and metrorrhagia. The treatment can be medical or surgical. Within this last group there is the possibility of performing a myomectomy or a total or subtotal hysterectomy. The subtotal hysterectomy allows the uterine cervix to be maintained and therefore the surgical technique is simpler. However, it requires the morcellation of the piece for its removal. Alternatively, total hysterectomy eliminates the risk of recurrence of uterocervical pathology, but this procedure presents a steeper learning curve. CLINICAL CASE: We present the case of a patient of 52 years who underwent a laparoscopic supracervical hysterectomy for myomas. Subsequently, the appearance of a new myoma in the cervical remnant was observed, which required a vaginal trachelectomy. CONCLUSION: Laparoscopic subtotal hysterectomy in myomatous uterus can have as an adverse effect myomatous recurrence in the cervix or the appearance of parasitic myomas secondary to non-contained uterine morcellation. In addition, it involves continuing screening for the prevention of cervical cancer.


Assuntos
Humanos , Feminino , Pessoa de Meia-Idade , Neoplasias do Colo do Útero/cirurgia , Traquelectomia , Histerectomia/efeitos adversos , Leiomioma/cirurgia , Reoperação , Neoplasias do Colo do Útero/etiologia , Laparoscopia/efeitos adversos , Morcelação/efeitos adversos , Histerectomia/métodos , Leiomioma/etiologia , Recidiva Local de Neoplasia
15.
J Glob Antimicrob Resist ; 23: 417-419, 2020 12.
Artigo em Inglês | MEDLINE | ID: mdl-33212285

RESUMO

OBJECTIVES: We report the successful treatment of a bloodstream infection caused by Klebsiella pneumoniae harbouring NDM-1 using aztreonam-ceftazidime-avibactam in a neutropenic patient in whom colistin and meropenem therapy had previously failed. METHODS: A clinical isolate was evaluated to determine the presence of NDM, TEM, SHV, CTX, and CMY, and the killing kinetics of aztreonam (ATM; 4 µg/mL), aztreonam-avibactam (ATM-AVI; 4/4 µg/mL), and colistin (2 and 4 µg/mL) were tested. RESULTS: ATM-AVI showed in vitro activity against the Klebsiella pneumoniae harbouring NDM-1, whereas colistin allowed re-growth. CONCLUSIONS: This report supports reconsideration of use of colistin for treatment of infections caused by K. pneumoniae harbouring NDM. CZA/ATM use should be kept in mind as a treatment option, perhaps earlier than colistin.


Assuntos
Bacteriemia , Infecções por Klebsiella , Antibacterianos/uso terapêutico , Compostos Azabicíclicos , Aztreonam/uso terapêutico , Bacteriemia/tratamento farmacológico , Ceftazidima , Combinação de Medicamentos , Humanos , Infecções por Klebsiella/tratamento farmacológico , Klebsiella pneumoniae , Testes de Sensibilidade Microbiana , beta-Lactamases
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA